Related references
Note: Only part of the references are listed.Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Patrick G. Morris et al.
CLINICAL BREAST CANCER (2018)
被撤回的出版物: Dasatinib promotes TRAIL-mediated apoptosis by upregulating CHOP-dependent death receptor 5 in gastric cancer (Retracted article. See vol. 13, pg. 798, 2023)
Xiaona Wang et al.
FEBS OPEN BIO (2018)
FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies
Stephane Thibodeau et al.
JOURNAL OF CLINICAL MEDICINE (2018)
The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
Sofia Palacio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T. R. J. Evans et al.
ANNALS OF ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Yuichi Sesumi et al.
LUNG CANCER (2017)
Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
Eri Takiguchi et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M. Parseghian et al.
CLINICAL CANCER RESEARCH (2017)
Role of paclitaxel on critical nucleation concentration of tubulin and its effects thereof
Sankalp Verma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src
Yan Diao et al.
CANCER LETTERS (2016)
Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells
Juan Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death
Elin Hallan Naderi et al.
MOLECULAR CANCER (2015)
Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
Juan Xiao et al.
MOLECULAR MEDICINE REPORTS (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells
Hong-Quan Duong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity
Sook-Kyoung Heo et al.
PLOS ONE (2014)
Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer
Ali Arshad et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
Siyuan Zhang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
Src family kinases and paclitaxel sensitivity
Xiao-Feng Le et al.
CANCER BIOLOGY & THERAPY (2011)
Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Nagathihalli S. Nagaraj et al.
CLINICAL CANCER RESEARCH (2011)
Overcoming drug resistance in pancreatic cancer
Jiang Long et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dasatinib Induces Autophagic Cell Death in Human Ovarian Cancer
Xiao-Feng Le et al.
CANCER (2010)
Targeting SRC in glioblastoma tumors and brain metastases Rationale and preclinical studies
Manmeet S. Ahluwalia et al.
CANCER LETTERS (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
John Araujo et al.
CANCER TREATMENT REVIEWS (2010)
Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Nagathihalli S. Nagaraj et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2009)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
Src and focal adhesion kinase as therapeutic targets in cancer
Valerie G. Brunton et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling
I. Ischenko et al.
ONCOGENE (2008)
Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
MS Duxbury et al.
CLINICAL CANCER RESEARCH (2004)
c-Src and cooperating partners in human cancer
R Ishizawar et al.
CANCER CELL (2004)
Activation of Src kinase in primary colorectal carcinoma - An indicator of poor clinical prognosis
H Allgayer et al.
CANCER (2002)
Share Paper
